PTAB Declines To Enter Adverse Judgment Against Pre-Institution Disclaimed Claims, PTAB Litigation Blog
Visit the PTAB Litigation Blog.
Although the Federal Circuit had previously held that the PTAB may enter adverse judgment when a patent owner disclaims all claims challenged in an inter partes review (“IPR”) petition before an institution decision, in Pfizer, Inc. v. UniQure Biopharma B.V., IPR2020-00388, Paper 52 (Mar. 25, 2021), the PTAB declined to enter adverse judgment against challenged claims that the patent owner had disclaimed before the PTAB instituted review.
Insights by Jones Day should not be construed as legal advice on any specific facts or circumstances. The contents are intended for general information purposes only and may not be quoted or referred to in any other publication or proceeding without the prior written consent of the Firm, to be given or withheld at our discretion. To request permission to reprint or reuse any of our Insights, please use our “Contact Us” form, which can be found on our website at www.jonesday.com. This Insight is not intended to create, and neither publication nor receipt of it constitutes, an attorney-client relationship. The views set forth herein are the personal views of the authors and do not necessarily reflect those of the Firm.
